Cue Biopharma (Nasdaq:CUE) - Aandelenkoers, Nieuws & Analyse

CUE Overzicht aandelen

CUE fundamentele analyse
Sneeuwvlok Score
Waardering	1/6
Toekomstige groei	2/6
Prestaties in het verleden	0/6
Financiële gezondheid	3/6
Dividenden	0/6

Beloningen

De omzet zal naar verwachting met 33% per jaar groeien

Risicoanalyse

Heeft minder dan 1 jaar cash runway

De winst zal naar verwachting de komende drie jaar met gemiddeld 2.1% per jaar dalen.

Zeer volatiele aandelenkoers in de afgelopen 3 maanden

Momenteel verlieslatend en er wordt niet verwacht dat dit de komende 3 jaar winstgevend zal worden.

+ 2 meer risico's

Cue Biopharma, Inc. Concurrenten

Seres Therapeutics

NasdaqGS:MCRB

US$124.6m

Karyopharm Therapeutics

NasdaqGS:KPTI

US$97.4m

Elutia

NasdaqCM:ELUT

US$149.9m

Agenus

NasdaqCM:AGEN

US$67.1m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Cue Biopharma
Historische aandelenkoersen
Huidige aandelenkoers	US$1.02
52 Week Hoogtepunt	US$3.25
52 Week Laag	US$0.45
Bèta	1.8
11 maand verandering	-35.03%
3 maanden verandering	32.55%
1 Jaar Verandering	-58.20%
33 jaar verandering	-92.04%
5 jaar verandering	-91.39%
Verandering sinds IPO	-91.23%

Recent nieuws en updates

Recent updates

Cue Biopharma shares rise ~10% on FDA fast track nod for head and neck cancer drug

Oct 04

Despite Lacking Profits Cue Biopharma (NASDAQ:CUE) Seems To Be On Top Of Its Debt

Sep 23

News Flash: 4 Analysts Think Cue Biopharma, Inc. (NASDAQ:CUE) Earnings Are Under Threat

Aug 26

Analysts Just Shipped A Huge Upgrade To Their Cue Biopharma, Inc. (NASDAQ:CUE) Estimates

Aug 10

Analysts Have Just Cut Their Cue Biopharma, Inc. (NASDAQ:CUE) Revenue Estimates By 23%

May 18

Cue Biopharma (NASDAQ:CUE) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

May 12

Cue Biopharma: A First Assessment

May 11

Earnings Beat: Cue Biopharma, Inc. (NASDAQ:CUE) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Mar 19

Cue Biopharma: Too Long To Arrive At Topline Trial Data

Feb 23

We Think Cue Biopharma (NASDAQ:CUE) Can Afford To Drive Business Growth

Nov 04

Rendement voor aandeelhouders

	CUE	US Biotechs	US Markt
7D	-18.1%	-3.7%	0.3%
1Y	-58.2%	15.2%	31.1%

Rendement versus industrie: CUE presteerde slechter dan de US Biotechs -sector, die het afgelopen jaar een rendement van 15.2 % opleverde.

Rendement versus markt: CUE presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 31.1 % opleverde.

Prijsvolatiliteit

Is CUE's price volatile compared to industry and market?
CUE volatility
CUE Average Weekly Movement	26.3%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.2%
10% most volatile stocks in US Market	15.8%
10% least volatile stocks in US Market	3.1%

Stabiele aandelenkoers: De aandelenkoers van CUE is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit van CUE is het afgelopen jaar gestegen van 18% naar 26%.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2014	53	Dan Passeri	www.cuebiopharma.com

Cue Biopharma, Inc., een biofarmaceutisch bedrijf in een klinische fase, ontwikkelt een nieuwe klasse injecteerbare geneesmiddelen om selectief gerichte, ziekterelevante T-cellen direct in het lichaam van de patiënt aan te spreken en te moduleren. De belangrijkste kandidaat is CUE-101 voor de behandeling van door het humaan papillomavirus (HPV16+) veroorzaakte terugkerende/metastatische hoofd-halskanker. Het bedrijf ontwikkelt ook CUE-102, gericht tegen Wilms' Tumor 1 eiwit in verschillende vormen van kanker; CUE-103, een kandidaat-geneesmiddel uit de CUE-100 serie; en Neo-STAT en RDI-STAT programma's buiten de oncologie, waaronder CUE-200, CUE-300 en CUE-400 series.

Cue Biopharma, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Cue Biopharma zich tot de beurswaarde?
CUE fundamentele statistieken
Marktkapitalisatie	US$65.25m
Inkomsten(TTM)	-US$44.61m
Inkomsten(TTM)	US$9.53m

6.8x

P/S-verhouding

-1.4x

Koers/Winstverhouding

Is CUE overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
CUE resultatenrekening (TTM)
Inkomsten	US$9.53m
Kosten van inkomsten	US$37.29m
Brutowinst	-US$27.76m
Overige uitgaven	US$16.85m
Inkomsten	-US$44.61m

Laatst gerapporteerde inkomsten

Sep 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-0.70
Brutomarge	-291.24%
Nettowinstmarge	-468.02%
Schuld/Eigen Vermogen Verhouding	20.9%

Hoe presteerde CUE op de lange termijn?

Bekijk historische prestaties en vergelijking

CUE Overzicht aandelen

Beloningen

Risicoanalyse

Cue Biopharma, Inc. Concurrenten

NasdaqGS:MCRB

US$124.6m

NasdaqGS:KPTI

US$97.4m

NasdaqCM:ELUT

US$149.9m

NasdaqCM:AGEN

US$67.1m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Cue Biopharma Announces Strategic Organizational Transition

Cue Biopharma, Inc. Presents Positive Updated Data from its Phase 1 Trials of CUE-101 and CUE-102 in Head and Neck Cancer and WT1 Positive Cancers at the SITC 39th Annual Meeting

Cue Biopharma, Inc. has completed a Follow-on Equity Offering in the amount of $12 million.

New major risk - Share price stability

Cue Biopharma, Inc. has completed a Follow-on Equity Offering in the amount of $12 million.

Recent updates

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Cue Biopharma Announces Strategic Organizational Transition

Cue Biopharma, Inc. Presents Positive Updated Data from its Phase 1 Trials of CUE-101 and CUE-102 in Head and Neck Cancer and WT1 Positive Cancers at the SITC 39th Annual Meeting

Cue Biopharma, Inc. has completed a Follow-on Equity Offering in the amount of $12 million.

New major risk - Share price stability

Cue Biopharma, Inc. has completed a Follow-on Equity Offering in the amount of $12 million.

Cue Biopharma, Inc. Appoints Lucinda Warren as Chief Business Officer

Consensus estimates of losses per share improve by 20%

Cue Biopharma Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirement

Cue Biopharma Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirement

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Price target decreased by 15% to US$8.00

Cue Biopharma, Inc.(NasdaqCM:CUE) dropped from Russell Small Cap Completeness Index

Cue Biopharma, Inc. Appoints Michael J. Fox to the Board of Directors and the Compensation Committee

Consensus revenue estimates increase by 17%

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Cue Biopharma, Inc., Annual General Meeting, Jun 05, 2024

Here's Why Cue Biopharma (NASDAQ:CUE) Can Manage Its Debt Despite Losing Money

New major risk - Revenue and earnings growth

Consensus EPS estimates fall by 20%

Full year 2023 earnings: EPS and revenues exceed analyst expectations

New major risk - Revenue and earnings growth

New minor risk - Market cap size

Does Cue Biopharma (NASDAQ:CUE) Have A Healthy Balance Sheet?

Consensus revenue estimates decrease by 25%

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Cue Biopharma Presents New Positive Data from Phase 1 Trials of CUE-101 in Head and Neck Cancer and Cue-102 in Wilms' Tumor 1 Positive Cancers at SITC 2023

New minor risk - Share price stability

Cue Biopharma Announces Completion of Patient Enrollment in Phase 1b Study of CUE-101 in Combination with KEYTRUDA®?

Cue Biopharma, Inc. Announces Resignation of Aaron Fletcher as Member of the Board of Directors, Effective October 9, 2023

Is Cue Biopharma (NASDAQ:CUE) Using Too Much Debt?

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Cue Biopharma, Inc. Presents Positive Data Update from Ongoing Phase 1 Trials of Cue-101 for Recurrent/Metastatichpv+ Head and Neck Squamous Cell Carcinoma At the 2023 American Society of Clinical Oncology Annual Meeting

Consensus revenue estimates decrease by 91%, EPS upgraded

Cue Biopharma, Inc. has completed a Follow-on Equity Offering in the amount of $17.6 million.

First quarter 2023 earnings: EPS in line with expectations, revenues disappoint

Consensus revenue estimates fall by 24%

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Cue Biopharma, Inc. Announces the Appointment of Rafi Ahmed to its Scientific Advisory Board

Cue Biopharma, Inc. Announces Executive Changes

Consensus forecasts updated

Cue Biopharma, Inc. announced that it expects to receive $29.999992 million in funding

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Cue Biopharma, Inc. Presents New Positive Data from Ongoing Phase 1 Trial of Cue-101 in Combination with Keytruda for Recurrent/Metastatic Hpv+ Head and Neck Cancer At the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting

Cue Biopharma Grants FDA Fast Track Designation for CUE-101 for the Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Cue Biopharma shares rise ~10% on FDA fast track nod for head and neck cancer drug

Despite Lacking Profits Cue Biopharma (NASDAQ:CUE) Seems To Be On Top Of Its Debt

News Flash: 4 Analysts Think Cue Biopharma, Inc. (NASDAQ:CUE) Earnings Are Under Threat

Consensus revenue estimates fall by 50%

Cue Biopharma Doses First Patient in Phase 1 Study of CUE-102 for Wilms’ Tumor 1 (WT1) - Expressing Cancers

Consensus revenue estimates increase by 54%

Analysts Just Shipped A Huge Upgrade To Their Cue Biopharma, Inc. (NASDAQ:CUE) Estimates

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Cue Biopharma, Inc. Announces Resignation of Cameron Gray as Member of the Board of Directors and All Committees

Insider recently bought US$105k worth of stock

Analysts Have Just Cut Their Cue Biopharma, Inc. (NASDAQ:CUE) Revenue Estimates By 23%

Consensus revenue estimates fall by 23%

Cue Biopharma (NASDAQ:CUE) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

U.S. Food and Drug Administration Accepts Cue Biopharma, Inc Investigational New Drug Application